secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001104659-24-117691
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics reports Q3 2024 net loss of $34M; first patients dosed in Phase 2b ACCESS obesity study
--------------------------------------------------------------------------------

- Cash, cash equivalents and short-term investments $915.3M; expected to fund operations through at least 2027 excluding Phase 3 registrational studies.
- Net loss $34.0M for Q3 2024 vs $23.9M in Q3 2023; R&D expenses $32.6M (up from $17.5M) driven by GLP-1R program advancement.
- First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity; topline data expected Q4 2025.
- Oral amylin receptor agonist development candidate expected by end of 2024; GIPR candidate expected H1 2025.
- ANPA-0073 (APJR agonist) Phase 2 ready; long-term toxicology studies ongoing, expected completion in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465924117691/0001104659-24-117691-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465924117691/tm2428324d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-117691

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer